Manuel Röhrich, Johanna Daum, Ewgenija Gutjahr, Anna-Maria Spektor, Frederik M Glatting, Yasemin Aylin Sahin, Hans Georg Buchholz, Jorge Hoppner, Cathrin Schroeter, Eleni Mavriopoulou, Kai Schlamp, Matthias Grott, Florian Eichhorn, Claus Peter Heußel, Hans Ulrich Kauczor, Michael Kreuter, Frederik Giesel, Mathias Schreckenberger, Hauke Winter, Uwe Haberkorn
PET using 68 Ga-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) holds high potential for diagnostic imaging of various malignancies, including lung cancer (LC). However, 18 F-FDG PET is still the clinical gold standard for LC imaging. Several subtypes of LC, especially lepidic LC, are frequently 18 F-FDG PET-negative, which markedly hampers the assessment of single pulmonary lesions suggestive of LC. Here, we evaluated the diagnostic potential of static and dynamic 68 Ga-FAPI-46 PET in the 18 F-FDG-negative pulmonary lesions of 19 patients who underwent surgery or biopsy for histologic diagnosis after PET imaging...
April 11, 2024: Journal of Nuclear Medicine